MedTrace Logo

A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia

NCT02979704 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-12-02

No results posted yet for this study

Summary

This study will be conducted to assess the status of oxidative stress inflammation and thrombogenesis in patients with hyperlipidemia and to compare the antioxidative, anti-inflammatory and antithrombogenic effects of rosuvastatin and atorvastatin.

Conditions

Interventions

DRUG

Rosuvastatin

45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks

DRUG

Atorvastatin

45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks

Sponsors & Collaborators

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    lead OTHER

Principal Investigators

  • Samia Tonu, MBBS · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-06-30
Completion
2017-07-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02979704 on ClinicalTrials.gov